Newsroom
News

Isomorphic Labs Raises $5 Billion Series C, the Largest Biotech Venture Round Ever

Isomorphic Labs, the DeepMind spin-out, has raised $5bn in a Series C co-led by Greenoaks and Sequoia to take its AI-designed drug candidates to clinical trials — the largest venture round in biotech history.

Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor alongside Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. It follows a $2.1 billion Series B in May, and is the largest venture round in biotech history, surpassing the $3 billion Altos Labs raised at its 2022 launch. The funding will develop IsoDDE, Isomorphic's drug-design engine, and build AI-led clinical infrastructure. Founder and CEO Demis Hassabis has said the company expects its first clinical trials by the end of 2026.

TechCrunch

techcrunch.com

Share

More from the newsroom